Testing effectiveness (Phase 2)Not Yet RecruitingNCT07287202
What this trial is testing
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
Who this might be right for
Focal Cortical DysplasiaTuberous Sclerosis Complex (TSC)Hemimegalencephaly
Sovargen 15